<DOC>
	<DOC>NCT00443729</DOC>
	<brief_summary>The purpose of this study is to investigate the efficacy, safety, and tolerability of an investigational treatment for patients with Human Immunodeficiency Virus (HIV).</brief_summary>
	<brief_title>MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-033)(TERMINATED)</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Patient is at least 18 years of age Patient is human immunodeficiency virus (HIV) positive Patient has documented Human Immunodeficiency Virus (HIV) RiboNucleic Acid (RNA) &lt;50 copies/milliliter (mL) for at least 3 months while on a KALETRA based regimen Patient has been on a KALETRA based regimen for at least 3 months without a change in background antiretroviral therapy Patient has no documentation of HIV RNA &gt;50 copies/mL for at least 3 months while on the KALETRA based regimen Patient is or plans to become pregnant, or is nursing a child Patient plans to donate eggs or impregnate/donate sperm Patient is receiving Stavudine (d4T) as a component of the background antiretroviral therapy Patient is currently receiving a second protease inhibitor in addition to KALETRA Patient is currently receiving, or has received in the past twelve weeks, treatment for the management of elevated lipids Patient has used another experimental HIVintegrase inhibitor Patient has a current (active) diagnosis of acute hepatitis due to any cause</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>treatment experienced</keyword>
</DOC>